丁苯酞胶囊联合长春西汀治疗后循环缺血性眩晕的疗效评价
|
摘要
目的评价和分析后循环缺血性眩晕患者应用丁苯酞胶囊联合长春西汀治疗的临床疗效。方法随机选择93例2017年1月—2018年1月在该院接受后循环缺血性眩晕治疗的患者,将接受长春西汀注射液治疗的患者纳入对比组(n=45),将接受长春西汀注射液联合丁苯酞胶囊治疗的患者纳入研究组(n=48),所有患者均接受降糖治疗、降压治疗以及降脂治疗等常规治疗,同时口服阿司匹林肠溶片。结果研究组患者临床总缓解率明显高于对比组患者,2组患者临床总缓解率经对比差异有统计学意义(χ~2=10.39 2 0,P=0.020 3),用药后47例研究组患者病情得到缓解,1例患者治疗无效,37例对比组患者病情得到缓解。治疗后2组患者各项观察项目均获得一定程度的改善,研究组患者BA血流速度高于对比组,2组数据差异有统计学意义(t=17.923 9,P=0.027 3),RVA血流速度高于对比组,2组数据差异有统计学意义(t=13.203 4,P=0.018 3),LVA血流速度高于对比组,2组数据差异有统计学意义(t=15.726 7,P=0.012 9)。结论后循环缺血性眩晕患者应用丁苯酞胶囊联合长春西汀治疗效果明显优于单一用药,可促进患者病情缓解。
Objective To evaluate and analyze the clinical efficacy of butylphthalide capsule combined with vinpocetine in patients with posterior circulation ischemic vertigo. Methods Ninety-three patients with post-circulatory ischemic vertigo who were treated in our hospital from January 2017 to January 2018 were randomly selected. Patients who received vinpocetine injection were included in the control group(n=45) and treated with vinpocetine combined with butylphthalide capsules were enrolled in the study group( n=48). All patients received routine treatments such as hypoglycemic therapy, antihypertensive therapy, and lipid-lowering therapy, and oral as-pirin enteric-coated tablets. Results The overall clinical remission rate of the study group was significantly higher than that of the control group. The clinical total remission rate of the two groups was statistically significant( χ~2=10.392 0, P=0.020 3). After treatment,47 patients in the study group were relieved. One patient was ineffective and 37 patients in the control group were relieved. After treatment, the observation items of the two groups were improved to a certain extent. The BA blood flow velocity in the study group was higher than that in the control group. The difference between the two groups was statistically significant( t=17.923 9, P=0.027 3),and the RVA blood flow velocity. Compared with the control group, the difference between the two groups was statistically significant(t=13.203 4, P=0.018 3). The blood flow velocity of LVA was higher than that of the control group. The difference between the two groups was statistically significant(t=15.726 7, P=0.012 9). Conclusion The application of butylphthalide capsule combined with vinpocetine in patients with posterior circulation ischemic vertigo is significantly better than single drug, which can promote the patient's condition.
Objective To evaluate and analyze the clinical efficacy of butylphthalide capsule combined with vinpocetine in patients with posterior circulation ischemic vertigo. Methods Ninety-three patients with post-circulatory ischemic vertigo who were treated in our hospital from January 2017 to January 2018 were randomly selected. Patients who received vinpocetine injection were included in the control group(n=45) and treated with vinpocetine combined with butylphthalide capsules were enrolled in the study group( n=48). All patients received routine treatments such as hypoglycemic therapy, antihypertensive therapy, and lipid-lowering therapy, and oral as-pirin enteric-coated tablets. Results The overall clinical remission rate of the study group was significantly higher than that of the control group. The clinical total remission rate of the two groups was statistically significant( χ~2=10.392 0, P=0.020 3). After treatment,47 patients in the study group were relieved. One patient was ineffective and 37 patients in the control group were relieved. After treatment, the observation items of the two groups were improved to a certain extent. The BA blood flow velocity in the study group was higher than that in the control group. The difference between the two groups was statistically significant( t=17.923 9, P=0.027 3),and the RVA blood flow velocity. Compared with the control group, the difference between the two groups was statistically significant(t=13.203 4, P=0.018 3). The blood flow velocity of LVA was higher than that of the control group. The difference between the two groups was statistically significant(t=15.726 7, P=0.012 9). Conclusion The application of butylphthalide capsule combined with vinpocetine in patients with posterior circulation ischemic vertigo is significantly better than single drug, which can promote the patient's condition.
引文
[1]张唯聪.浅析丁苯酞联合前列地尔注射液治疗后循环缺血性眩晕的临床效果[J].中国卫生标准管理,2017,8(25):66-67.
[2]郭岩林.丁苯酞胶囊联合长春西汀治疗后循环缺血性眩晕的疗效观察[J].中国社区医师:医学专业,2013,15(10):52.
[3]刘雅芳,黄咏梅,戴军,等.丁苯酞联合前列地尔注射液治疗后循环缺血性眩晕的临床效果[J].中国医药导报,2017,14(18):145-148.
[4]陈统华.长春西汀治疗后循环缺血性眩晕的疗效及优势[J].黑龙江医药,2017,30(6):1259-1261.
[5]龚建祖,程伟.丁苯酞联合长春西汀治疗椎动脉优势型后循环缺血性眩晕的疗效及安全性分析[J].医学临床研究,2016,33(11):2088-2091.
[6]李冉冉,徐鸿华.长春西汀注射液治疗后循环缺血性眩晕的临床疗效[J].中国现代应用药学,2015,32(1):104-107.
[7]徐国民,顾卫国,蔡利.丹参川芎嗪联合长春西汀治疗后循环缺血性眩晕疗效观察[J].实用中医药杂志,2017,33(10):1188-1189.
[8]赵红卫,刘艳新,范波胜.低分子肝素钙联合长春西汀治疗后循环缺血性眩晕的疗效[J].中国实用神经疾病杂志,2014(17):121-122.
[9]高宁,王令.丁苯酞注射液治疗后循环缺血性头晕的临床观察[J].河北医药,2016(4):594-595.
[10]赵文斌.丁苯酞注射液治疗后循环缺血性头晕临床效果观察[J].健康前沿,2016,23(7):194.
[11]刘晓琳,王进.丁苯酞注射液治疗后循环缺血性头晕的效果观察[J].中国药物经济学,2018,13(1):119-120,128.
[2]郭岩林.丁苯酞胶囊联合长春西汀治疗后循环缺血性眩晕的疗效观察[J].中国社区医师:医学专业,2013,15(10):52.
[3]刘雅芳,黄咏梅,戴军,等.丁苯酞联合前列地尔注射液治疗后循环缺血性眩晕的临床效果[J].中国医药导报,2017,14(18):145-148.
[4]陈统华.长春西汀治疗后循环缺血性眩晕的疗效及优势[J].黑龙江医药,2017,30(6):1259-1261.
[5]龚建祖,程伟.丁苯酞联合长春西汀治疗椎动脉优势型后循环缺血性眩晕的疗效及安全性分析[J].医学临床研究,2016,33(11):2088-2091.
[6]李冉冉,徐鸿华.长春西汀注射液治疗后循环缺血性眩晕的临床疗效[J].中国现代应用药学,2015,32(1):104-107.
[7]徐国民,顾卫国,蔡利.丹参川芎嗪联合长春西汀治疗后循环缺血性眩晕疗效观察[J].实用中医药杂志,2017,33(10):1188-1189.
[8]赵红卫,刘艳新,范波胜.低分子肝素钙联合长春西汀治疗后循环缺血性眩晕的疗效[J].中国实用神经疾病杂志,2014(17):121-122.
[9]高宁,王令.丁苯酞注射液治疗后循环缺血性头晕的临床观察[J].河北医药,2016(4):594-595.
[10]赵文斌.丁苯酞注射液治疗后循环缺血性头晕临床效果观察[J].健康前沿,2016,23(7):194.
[11]刘晓琳,王进.丁苯酞注射液治疗后循环缺血性头晕的效果观察[J].中国药物经济学,2018,13(1):119-120,128.